Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (18)

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

2022

  1. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681

  2. Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441

    European Urology

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. Prediction of major bleeding in anticoagulated patients for venous thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores

    TH Open, Vol. 5, Núm. 3, pp. e319-e328

  3. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial

    Radiotherapy and Oncology, Vol. 160, pp. 115-119

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

  3. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

2016

  1. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia

    British Journal of Cancer, Vol. 114, Núm. 11, pp. 1191-1198

  2. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial

    International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348

2015

  1. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial

    The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327

2014

  1. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 447-454

2013

  1. Practice patterns in the management of prostate cancer in Spain: Results from a national survey among radiation oncologists in 2009

    Clinical and Translational Oncology, Vol. 15, Núm. 3, pp. 226-232

2008

  1. Randomised study of single dose (8 Gy vs. 6 Gy) of analgesic radiotherapy plus zoledronic acid in patients with bone metastases

    Clinical and Translational Oncology, Vol. 10, Núm. 5, pp. 281-287

2006

  1. Intensificación terapéutica intraoperatoria en el tratamiento de los sarcomas abdominales localmente avanzados

    Cirugia Espanola, Vol. 80, Núm. 4, pp. 200-205

2005

  1. Erythropoietin in cancer treatment: Considerations about Henke's article

    Clinical and Translational Oncology

  2. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study

    Journal of Clinical Oncology, Vol. 23, Núm. 27, pp. 6561-6568